Relmada Therapeutics, Inc. (RLMD) Financial Statements
Free cash flow over the same period: -$46.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RLMDRelmada Therapeutics, Inc.Follow RLMD — free
—
Price chart with a free account
- Market cap
- 348.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2013 Dec 13 | FY2015 Jun 15 | FY2016 Jun 16 | FY2017 Jun 17 | FY2018 Jun 18 | FY2019 Jun 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | 5.2 | 7.9 | 6.2 | 1.3 | 2.9 | 7.0 | 36.0 | 90.6 | 113.3 | 54.8 | 46.2 | 26.9 | 28.6 | |
| Operating income | -6.8 | -17.1 | -16.2 | -7.2 | -6.9 | -12.7 | -60.8 | -125.7 | -161.2 | -103.7 | -83.9 | -59.1 | -65.1 | |
| Pre-tax income | -19.9 | -20.8 | -3.0 | -6.3 | -9.0 | — | — | -125.8 | -157.0 | — | -80.0 | -57.4 | -61.9 | |
| Net income | -19.9 | -20.8 | -3.0 | -6.3 | -9.0 | -17.3 | -59.5 | -125.8 | -157.0 | -98.8 | -80.0 | -57.4 | -61.9 | |
| Diluted EPS ($) | -40.90 | -2.09 | -0.26 | -0.52 | -2.86 | -2.74 | -3.81 | -7.16 | -5.30 | -3.28 | -2.65 | -1.45 | -0.54 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | 29.6 | 30.1 | 30.2 | 39.5 | — |
USD millions · SEC XBRL
Relmada Therapeutics, Inc. — questions
- What is Relmada Therapeutics, Inc.'s net income?
- -$61.9M over the twelve months to 2026-06-30.
- What is Relmada Therapeutics, Inc.'s free cash flow?
- -$46.0M over the twelve months to 2026-06-30.
- What are Relmada Therapeutics, Inc.'s diluted earnings per share?
- $-0.54 over the twelve months to 2026-06-30.
Every figure on this page comes from Relmada Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.